CJC-1295, with DAC

This record concerns the long-acting CJC-1295 studied in human hormone experiments. The supplier match is still unverified.

Sources for this tile

• CJC-1295: controlled human hormone studies (Teichman and colleagues · 2006 · Published abstract · checked 2026-10-08)

Controlled early studies measured growth hormone and IGF-1. They did not establish better ageing, strength or appearance.

Sources for this tile

• CJC-1295: controlled human hormone studies (Teichman and colleagues · 2006 · Published abstract · checked 2026-10-08)

Open the pathway notes below. A biological pathway is a possible chain of events in the body. The grade states where it was tested.

Sources for this tile

• CJC-1295: controlled human hormone studies (Teichman and colleagues · 2006 · Published abstract · checked 2026-10-08)

Each proposed mechanism

Hormone markers

The human studies measured increases in growth hormone and IGF-1. A marker increase is not the same as a health benefit.

Evidence note: A

Sources

• CJC-1295: controlled human hormone studies (Teichman and colleagues · 2006 · Published abstract · checked 2026-10-08)

Go deeper

Hormone markers A

The human studies measured increases in growth hormone and IGF-1. A marker increase is not the same as a health benefit.

Sources

• CJC-1295: controlled human hormone studies (Teichman and colleagues · 2006 · Published abstract · checked 2026-10-08)

Open the outcome notes. They show the tested condition and what was measured. A positive marker, a mouse result and a clinical benefit are different things.

Sources for this tile

• CJC-1295: controlled human hormone studies (Teichman and colleagues · 2006 · Published abstract · checked 2026-10-08)

Read this before you read a benefit into it

Laboratory and animal results describe what happened in that model. They are not proven healing in a person. Human studies name their own population, outcome and limits. Both are kept apart here on purpose.

Human research found for this product

CJC-1295: controlled human hormone studies A

Proof grade	A
Design	Two randomised placebo-controlled dose studies
People or model	Healthy adults aged 21-61
Outcome measured	GH, IGF-1 and drug exposure
Result	Growth hormone rose about 2-10-fold and IGF-1 about 1.5-3-fold. The reported half-life was 5.8-8.1 days.
Route in the study	Subcutaneous
Duration	28- and 49-day study periods
Risks noted	No serious reactions reported in these early studies.
Personal regimen	Not set. A study regimen is not a personal instruction.

Source

• CJC-1295: controlled human hormone studies (Teichman and colleagues · 2006 · Published abstract · checked 2026-10-08)

Go deeper

GH, IGF-1 and drug exposure A

A: Tested in Healthy adults aged 21-61. Read the study result in the human or researcher layer. This is a tested outcome, not a promised benefit.

Sources

• CJC-1295: controlled human hormone studies (Teichman and colleagues · 2006 · Published abstract · checked 2026-10-08)

Each claim keeps its own source, evidence grade and limits. This is a scoped first research edition. It is not a full review or a personal treatment plan.

Sources for this tile

• CJC-1295: controlled human hormone studies (Teichman and colleagues · 2006 · Published abstract · checked 2026-10-08)

Overall state of the evidence

Status: scoped-human-evidence

Participant count was not confirmed from the abstract. The paper supports hormone and exposure findings, not an anti-ageing outcome.

Risk summary

Participant count was not confirmed from the abstract. The paper supports hormone and exposure findings, not an anti-ageing outcome.

Unwanted effects reported in the sources

• No serious reactions reported in these early studies. (CJC-1295: controlled human hormone studies)

What is still open

• Supplier identity and batch match have not been verified
• Full-text systematic review and complete interactions are not finished
• Exact long-acting formulation
• Baseline hormone status
• Current medicines and glucose history

Checks a reviewer must finish first

• Exact long-acting formulation
• Baseline hormone status
• Current medicines and glucose history

How to read the proof grades

• A: Controlled human trial. Note whether randomisation and blinding were confirmed.
• B: Small uncontrolled human study or chart review.
• C: Whole-animal intervention.
• D: Cell or other laboratory study.
• E: User reports. Kept separate and never substituted for a measured outcome.
• ungraded: Identity sources, official labels, notices, reviews and unverified claims are not assigned an efficacy grade.

Go deeper

How to read the proof Open the checked detail

A: controlled human trial. State whether it was blinded and randomized. B: small uncontrolled human study or chart review; a weak clinical comparison is marked with its design limits. C: whole-animal work. D: cells or other lab work. E: user reports.

A grade describes the kind of evidence for one claim. It does not grade every claim about a peptide or approve a product. Labels, history and regulatory reviews are named sources, not efficacy grades.

Sources

• Future Health research method (Christopher’s supplied research method; read in full · checked 2026-10-09)

Open questions Open the checked detail

Supplier identity and batch match have not been verified

Full-text systematic review and complete interactions are not finished

Exact long-acting formulation

Baseline hormone status

Current medicines and glucose history

Open the linked human study records. Each names the tested group, design, result and limits. Related-compound and non-treatment studies are marked so they cannot be used as product treatment proof.

Sources for this tile

• CJC-1295: controlled human hormone studies (Teichman and colleagues · 2006 · Published abstract · checked 2026-10-08)

Studies named in this tile

Personal regimen	Not set. A study regimen is not a personal instruction.

What people report

No user reports are recorded for this product. The library keeps human studies and user reports in separate places, so nothing is filled in here.

Each human record

CJC-1295: controlled human hormone studies A

Proof grade	A
Design	Two randomised placebo-controlled dose studies
People or model	Healthy adults aged 21-61
Outcome measured	GH, IGF-1 and drug exposure
Result	Growth hormone rose about 2-10-fold and IGF-1 about 1.5-3-fold. The reported half-life was 5.8-8.1 days.
Route in the study	Subcutaneous
Duration	28- and 49-day study periods
Risks noted	No serious reactions reported in these early studies.
Personal regimen	Not set. A study regimen is not a personal instruction.

Source

• CJC-1295: controlled human hormone studies (Teichman and colleagues · 2006 · Published abstract · checked 2026-10-08)

This is the shared library. No client has been assessed in this record. This tile will use the person's own words, a named target and checked rule-outs after intake. A catalog entry does not mean it is suitable for someone.

Participant count was not confirmed from the abstract. The paper supports hormone and exposure findings, not an anti-ageing outcome.

Sources for this tile

• CJC-1295: controlled human hormone studies (Teichman and colleagues · 2006 · Published abstract · checked 2026-10-08)

Injections under the skin were studied. No client schedule is set. Research routes describe what was studied. They are not a client administration guide.

Sources for this tile

• CJC-1295: controlled human hormone studies (Teichman and colleagues · 2006 · Published abstract · checked 2026-10-08)

Routes seen in the research

• Subcutaneous

Dose and cycle fields in the library

These are blank on purpose. A personal amount, schedule, mixing or storage instruction is only written into an agreed plan after a reviewer checks the exact product.

Half-life and clearance

Half-life: [object Object]. Clearance: not established.